Building on these results, an ongoing study (NCT00262834) is evaluating change in tumor morphology, tissue and blood (peripheral blood mononuclear cells) histone acetylation, and safety of short term exposure to the HDAC inhibitor, vorinostat (Merck), for newly diagnosed breast cancers. Here, HDAC9 is linked to breast carcinoma.